CVD Risk Reduction and Lipid Management - 17

High Residual CVD Risk Remains Even with High-dose Rosuvastatin (JUPITER)
0.08

Placebo 251 / 8901

Primary trial endpoint: MI, Stroke, UA/ Revascularization, CV Death
Cumulative Incidence

HR 0.56, 95% CI 0.46-0.69 P < 0.00001

- 44 %

0.04

0.06

0.02

Rosuvastatin 20 mg/d 142 / 8901 Number Needed to Treat (NNT5) = 25

0.00 0
Number at Risk Rosuvastatin Placebo 8,901 8,901 8,631 8,621 8,412 8,353 6,540 6,508

1

2 Follow-up (years)
3,893 3,872 1,958 1,963

3
1,353 1,333 983 955

4
544 534 157 174

Ridker PM. N Engl J Med. 2008;359:2195-2207.



CVD Risk Reduction and Lipid Management

Table of Contents for the Digital Edition of CVD Risk Reduction and Lipid Management

CVD Risk Reduction and Lipid Management - 3
CVD Risk Reduction and Lipid Management - 5
CVD Risk Reduction and Lipid Management - 6
CVD Risk Reduction and Lipid Management - 7
CVD Risk Reduction and Lipid Management - 8
CVD Risk Reduction and Lipid Management - 9
CVD Risk Reduction and Lipid Management - 10
CVD Risk Reduction and Lipid Management - 11
CVD Risk Reduction and Lipid Management - 12
CVD Risk Reduction and Lipid Management - 13
CVD Risk Reduction and Lipid Management - 14
CVD Risk Reduction and Lipid Management - 15
CVD Risk Reduction and Lipid Management - 16
CVD Risk Reduction and Lipid Management - 17
CVD Risk Reduction and Lipid Management - 18
CVD Risk Reduction and Lipid Management - 19
CVD Risk Reduction and Lipid Management - 20
CVD Risk Reduction and Lipid Management - 21
CVD Risk Reduction and Lipid Management - 22
CVD Risk Reduction and Lipid Management - 23
CVD Risk Reduction and Lipid Management - 24
CVD Risk Reduction and Lipid Management - 25
CVD Risk Reduction and Lipid Management - 26
CVD Risk Reduction and Lipid Management - 27
CVD Risk Reduction and Lipid Management - 28
CVD Risk Reduction and Lipid Management - 29
CVD Risk Reduction and Lipid Management - 30
CVD Risk Reduction and Lipid Management - 31
CVD Risk Reduction and Lipid Management - 32
CVD Risk Reduction and Lipid Management - 33
CVD Risk Reduction and Lipid Management - 34
CVD Risk Reduction and Lipid Management - 35
CVD Risk Reduction and Lipid Management - 36
CVD Risk Reduction and Lipid Management - 37
CVD Risk Reduction and Lipid Management - 38
CVD Risk Reduction and Lipid Management - 39
CVD Risk Reduction and Lipid Management - 40
CVD Risk Reduction and Lipid Management - 41
CVD Risk Reduction and Lipid Management - 42
CVD Risk Reduction and Lipid Management - 43
CVD Risk Reduction and Lipid Management - 44
CVD Risk Reduction and Lipid Management - 45
CVD Risk Reduction and Lipid Management - 46
CVD Risk Reduction and Lipid Management - 47
CVD Risk Reduction and Lipid Management - 48
CVD Risk Reduction and Lipid Management - 49
CVD Risk Reduction and Lipid Management - 50
CVD Risk Reduction and Lipid Management - 51
CVD Risk Reduction and Lipid Management - 52
CVD Risk Reduction and Lipid Management - 53
CVD Risk Reduction and Lipid Management - 54
CVD Risk Reduction and Lipid Management - 55
CVD Risk Reduction and Lipid Management - 56
CVD Risk Reduction and Lipid Management - 57
CVD Risk Reduction and Lipid Management - 58
CVD Risk Reduction and Lipid Management - 59
CVD Risk Reduction and Lipid Management - 60
CVD Risk Reduction and Lipid Management - 61
CVD Risk Reduction and Lipid Management - 62
CVD Risk Reduction and Lipid Management - 63
CVD Risk Reduction and Lipid Management - 64
CVD Risk Reduction and Lipid Management - 65
CVD Risk Reduction and Lipid Management - 66
https://www.nxtbookmedia.com